New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin

References

• MunitaJMBayerASAriasCAEvolving resistance among Gram-positive pathogensClin Infect Dis201561suppl 2S48S5726316558
   PubMed Web of Science ®Google Scholar
• ScottLJDalbavancin: a review in acute bacterial skin and skin structure infectionsDrugs201575111281129126105117
   PubMed Web of Science ®Google Scholar
• ZhanelGCalicDSchweizerFNew glycopeptides: a comparative review of dalbavancin, oritavancin, and telavancinDrugs2011715860886
   Web of Science ®Google Scholar
• MoranGJAbrahamianFMLovecchioFAcute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelinesJ Emerg Med2013446e397e41223466022
   PubMedGoogle Scholar
• CattoirVLeclercqRTwenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce?J Antimicrob Chemother201368473174223208830
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFInfectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of AmericaClin Infect Dis2014592e10e5224973422
   PubMed Web of Science ®Google Scholar
• RodvoldKAMcConeghyKWMethicillin-resistant Staphylococcus aureus therapy: past, present, and futureClin Infect Dis201458suppl 1S20S2724343828
   PubMed Web of Science ®Google Scholar
• TenoverFCMoelleringRCJrThe rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusClin Infect Dis2007441208121517407040
   PubMed Web of Science ®Google Scholar
• BaeIGFederspielJJMiróJMInternational Collaboration on Endocarditis-Microbiology InvestigatorHeterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significanceJ Infect Dis200920091355136619811099
   PubMed Web of Science ®Google Scholar
• HowdenBPDaviesJKJohnsonPDReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsClin Microbiol Rev20102319913920065327
   PubMed Web of Science ®Google Scholar
• GuskeyMTTsujiBTA comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancinPharmacotherapy2010301809420030476
   PubMed Web of Science ®Google Scholar
• BennettJLewisJEllisMDalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewTher Clin Risk Manag200841314018728718
   PubMedGoogle Scholar
• ChenAZervosMVazquezJDalbavancin: a novel antimicrobialInt J Clin Prac2007615853863
   PubMed Web of Science ®Google Scholar
• MalabarbaAGoldsteinBOrigin, structure, and activity in vitro and in vivo of dalbavancinJ Antimicrob Chemother2005suppl S2ii15ii2015750032
   PubMed Web of Science ®Google Scholar
• GalesACSaderHSJonesRNAntimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centresClin Microbiol Infect20051129510015679482
   PubMed Web of Science ®Google Scholar
• BilleterMZervosMJChenAYDalovisioJRKurukularatneCDalbavancin: a novel once-weekly lipoglycopeptide antibioticClin Infect Dis200846457758318199045
   PubMed Web of Science ®Google Scholar
• LeightonAGottliebABDorrMBTolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteersAntimicrob Agents Chemother20044894094514982787
   PubMed Web of Science ®Google Scholar
• CavaleriMSimonaRValagussaAPharmacokinetics and excretion of dalbavancin in the ratJ Antimicrob Chemother200555suppl S2ii31ii3515750035
   PubMed Web of Science ®Google Scholar
• NicolauDPSunHKSeltzerEBuckwalterMDowellJAPharmacokinetics of dalbavancin in plasma and skin blister fluidJ Antimicrob Chemother200760368168417631507
   PubMed Web of Science ®Google Scholar
• Durata Therapeutics US LtdDalvance (dalbavancin) for injection, for intravenous use: US prescribing information2014 Available from: http://content.stockpr.com/duratatherapeutics/files/docs/Dalvance+APPROVED+USPI.PDFAccessed September 2, 2015
   Google Scholar
• BiedenbachDJBellJMSaderHSActivities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolatesAntimicrob Agents Chemother20095331260126319124664
   PubMed Web of Science ®Google Scholar
• BoucherHWilcoxMTalbotGOnce-weekly dalbavancin versus daily conventional therapy for skin infectionN Engl J Med20143702169217924897082
   PubMed Web of Science ®Google Scholar
• CampanileFBorboneSPerezMHeteroresistance to glycopeptides in Italian methicillin-resistant Staphylococcus aureus (MRSA) isolatesInt J Antimicrob Agents201036541541920727722
   PubMed Web of Science ®Google Scholar
• United States Food and Drug AdministrationFDA approves Dalvance to treat skin infections2014 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398724.htmAccessed September 6, 2015
   Google Scholar
• HellmarkBUnemoMNilsdotter-AugustinssonASöderquistBAntibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB geneClin Microbiol Infect200915323824419196261
   PubMed Web of Science ®Google Scholar
• BiedenbachDJRossJEFritscheTRActivity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesJ Clin Microb20074539981004
   PubMed Web of Science ®Google Scholar
• ZhanelGDeCorbyMNicholKAntimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006Diagn Microbiol Infect Dis200862678018513913
   PubMed Web of Science ®Google Scholar
• KarlowskyJAAdamHJPoutanenSMHobanDJZhanelGGIn vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 studyDiagn Microbiol Infect Dis201169334234721353963
   PubMed Web of Science ®Google Scholar
• CandianiGAbbondiMBorgonoviMRomanòGParentiFIn-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJ Antimicrob Chemother199944217919210473224
   PubMed Web of Science ®Google Scholar
• StreitJMSaderHSFritscheTRJonesRNDalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensDiagn Microbiol Infect Dis200553430731015922534
   PubMed Web of Science ®Google Scholar
• JonesRNSaderHSFlammRKUpdate of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)Diagn Microbiol Infect Dis201375330430723357293
   PubMed Web of Science ®Google Scholar
• DunneMWPuttaguntaSGiordanoPA randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infectionClin Infect Dis Epub20151126
   Google Scholar
• KlepserMFocus on dalbavancin: a novel long-acting lipoglycopeptide antibioticFormulary J2006 Available from: http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/focus-dalbavancin-novel-long-acting-lipoglycopAccessed September 6, 2015
   Google Scholar
• JonesRNSaderHSMendesREDalbavancin surveillance results for European Gram-positive species in a contemporary (2006–2009) sample of 23,825 strainsPoster 1129 presented at: 21st European Congress of Clinical Microbiology and Infectious DiseasesMay 7–10, 2011Milan
   Google Scholar